Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Adam

Showing results (111-120 of 152) with videos related to

Pageof 16
Sort By:
Cancers|October 3, 2020
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)Andrea De Giglio, Laura Mezquita, Edouard Auclin, et al.
Immunity|February 3, 2024
Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitisThomas M Savage, Katherine T Fortson, Kenia de Los Santos-Alexis, et al.
European Radiology|April 24, 2020
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinomaAlison Dormieux, Laura Mezquita, Paul Henry Cournede, et al.
Ebiomedicine|May 27, 2023
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancerFrançois Ghiringhelli, Frederic Bibeau, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)|September 3, 2023
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscapeAnne-Marie Lefebvre, Julien Adam, Céline Nicolazzi, et al.
Cancer Medicine|August 16, 2022
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective studySarah Watson, Benjamin Verret, Stanislas Ropert, et al.
Oncoimmunology|September 14, 2020
Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcomeKim L Brunekreeft, Sterre T Paijens, Maartje C A Wouters, et al.
Nature Medicine|October 31, 2018
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanomaMichaël Cerezo, Ramdane Guemiri, Sabine Druillennec, et al.
Cell Reports. Medicine|November 18, 2020
CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17Stéphanie Corgnac, Ines Malenica, Laura Mezquita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of <i>CTNNB1</i> Mutational StatusOlivier Mir, Charles Honoré, Ali N Chamseddine, et al.
Pageof 16

Showing results (111-120 of 152) with videos related to

Sort By:
Pageof 16
Cancers|October 3, 2020
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)Andrea De Giglio, Laura Mezquita, Edouard Auclin, et al.
Immunity|February 3, 2024
Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitisThomas M Savage, Katherine T Fortson, Kenia de Los Santos-Alexis, et al.
European Radiology|April 24, 2020
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinomaAlison Dormieux, Laura Mezquita, Paul Henry Cournede, et al.
Ebiomedicine|May 27, 2023
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancerFrançois Ghiringhelli, Frederic Bibeau, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)|September 3, 2023
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscapeAnne-Marie Lefebvre, Julien Adam, Céline Nicolazzi, et al.
Cancer Medicine|August 16, 2022
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective studySarah Watson, Benjamin Verret, Stanislas Ropert, et al.
Oncoimmunology|September 14, 2020
Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcomeKim L Brunekreeft, Sterre T Paijens, Maartje C A Wouters, et al.
Nature Medicine|October 31, 2018
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanomaMichaël Cerezo, Ramdane Guemiri, Sabine Druillennec, et al.
Cell Reports. Medicine|November 18, 2020
CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17Stéphanie Corgnac, Ines Malenica, Laura Mezquita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of <i>CTNNB1</i> Mutational StatusOlivier Mir, Charles Honoré, Ali N Chamseddine, et al.
Pageof 16